MA-LOADSPRING-SOLUTIONS
10.12.2020 17:29:10 CET | Business Wire | Press release
LoadSpring Solutions, a leading provider of global managed cloud solutions, announces a strategic collaboration with Google Cloud and SADA to provide clients with enhanced project analytics via Artificial Intelligence and Business Intelligence solutions. LoadSpring will combine its application, support, and project expertise with SADA's delivery expertise and Google Cloud infrastructure, solutions, and capabilities in AI and ML to help clients eliminate risks while increasing their insights and data access to make critical business and project decisions in real-time.
As a global leader in hosting, integrating, and providing access to software application data for project and asset-intensive organizations, LoadSpring recognizes the importance of access to a global technology footprint. Its customers operate worldwide and expect the same performance and support, whether in the Americas, Europe, the Middle East, or Pan-Asia. The new alliance will accelerate customer benefits, including one-stop managed cloud services, centralized support, and improved project command and control through LoadSpring Cloud Platform.
"The strategic alignment between our organizations is significant. The investments Google Cloud, SADA, and LoadSpring, are making to deliver best-in-class cloud solutions is transformational for our clients. I'm truly excited about the prospect of hosting, accessing, and leveraging years of data during the project life-cycle," said Dean Edmundson, Chief Strategy Officer at LoadSpring.
"Organizations today have an opportunity to transform business processes and derive more value out of their data with cloud capabilities in AI, ML, and analytics," said Dave Hutchison, Managing Director, Worldwide Channels at Google Cloud. "We are excited that LoadSpring and SADA will collaborate to help businesses leverage Google Cloud infrastructure and technologies to do so, and look forward to working together to drive digital transformation."
"We're excited to partner with LoadSpring to help them maximize the value of their Google Cloud investment," stated Simon Margolis, VP of CE, SADA. "The combined strength of our offerings will help clients expand their cloud, Business Intelligence, AI, and ML capabilities to achieve better project results."
ABOUT LOADSPRING
Founded in 1999, LoadSpring is a global cloud solutions provider obsessed with offering the highest level of managed cloud services. LoadSpring delivers expert Project Management solutions and fast access to project data, Business Intelligence, and hundreds of best-of-breed project-based applications. Data safety is assured through their SOC 2 Type II security certification, providing an impenetrable cloud environment. Through their proprietary LoadSpring Cloud Platform and their soon-to-be-launched LoadSpring Marketplace, customers and partners get effortless app provisioning, higher productivity, and ROI – all while reducing the burden on their IT departments.
ABOUT SADA
SADA is a leading global provider of business and technology services empowering people to transform their work, their organizations, and the world. SADA teams have helped enterprise clients in healthcare, media, entertainment, retail, manufacturing, and the public sector achieve their boldest ambitions and solve their most complex problems. A Google Cloud Partner with multiple Specializations, SADA delivers continuous innovation, strong partnerships, and service excellence. This has led to numerous accolades and awards, including the Google Cloud Global Reseller Partner of the Year for 2018 and 2019, the Inc. 5000 Honoree list of America's Fastest Growing Private Companies for 14 straight years, and the 2020 Inc. list of America's Top 50 Workplaces. More info at www.sada.com .
For more information, contact Stacey Witt at switt@loadspring.com or visit www.loadspring.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005791/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom